

# Kwun M Fong

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5509696/publications.pdf>

Version: 2024-02-01

176  
papers

10,112  
citations

47006

47  
h-index

39675

94  
g-index

181  
all docs

181  
docs citations

181  
times ranked

12682  
citing authors

#	ARTICLE	IF	CITATIONS
1	Lung cancer treatment patterns and factors relating to systemic therapy use in Australia. Asia-Pacific Journal of Clinical Oncology, 2022, 18, .	1.1	6
2	Overview of Lung Cancer. , 2022, , 621-633.		0
3	USPSTF2013 versus PLCOm2012 lung cancer screening eligibility criteria (International Lung Screening) Tj ETQq1 1 0,784314 rgBT /Q	10.7	66
4	Lung cancer screeningâ€”Marching along â€ . Respirology, 2022, 27, 578-580.	2.3	2
5	Improving lung health in low-income and middle-income countries: from challenges to solutions. Lancet, The, 2021, 397, 928-940.	13.7	176
6	A G316A Polymorphism in the Ornithine Decarboxylase Gene Promoter Modulates MYCN-Driven Childhood Neuroblastoma. Cancers, 2021, 13, 1807.	3.7	4
7	Postoperative adjuvant EGFR-TKIs for resected EGFR-mutant NSCLCâ€”opportunities and obstacles. Annals of Translational Medicine, 2021, 9, 586-586.	1.7	1
8	Plasma Extracellular Vesicle miRNAs Can Identify Lung Cancer, Current Smoking Status, and Stable COPD. International Journal of Molecular Sciences, 2021, 22, 5803.	4.1	19
9	Germline <i>ERBB3</i> mutation in familial non-small-cell lung carcinoma: expanding ErbBâ€™s role in oncogenesis. Human Molecular Genetics, 2021, 30, 2393-2401.	2.9	3
10	Determinants and Follow-up of Lung Function Data from a Predominantly First Nations Cohort of Adults Referred to Specialist Respiratory Outreach Clinics in Regional and Remote Queensland. Lung, 2021, 199, 417-425.	3.3	5
11	Alternative methods for local ablationâ€”interventional pulmonology: a narrative review. Translational Lung Cancer Research, 2021, 10, 3432-3445.	2.8	7
12	Associations between lung function and future cardiovascular morbidity and overall mortality in a predominantly First Nations population: a cohort study.. The Lancet Regional Health - Western Pacific, 2021, 13, 100188.	2.9	10
13	E-cigarettes induce toxicity comparable to tobacco cigarettes in airway epithelium from patients with COPD. Toxicology in Vitro, 2021, 75, 105204.	2.4	24
14	Validation of the Eighth Edition TNM Lung Cancer Staging System. Journal of Thoracic Oncology, 2020, 15, 649-654.	1.1	25
15	The IASLC Lung Cancer Staging Project: Analysis of Resection Margin Status and Proposals for Residual Tumor Descriptors for Nonâ€”Small Cell Lung Cancer. Journal of Thoracic Oncology, 2020, 15, 344-359.	1.1	87
16	Clinical impact of data feedback at lung cancer multidisciplinary team meetings: A mixed methods study. Asia-Pacific Journal of Clinical Oncology, 2020, 16, 45-55.	1.1	6
17	Lung Cancer in Australia. Journal of Thoracic Oncology, 2020, 15, 1809-1814.	1.1	13
18	Optimizing lung cancer MDT data for maximum clinical impactâ€”a scoping literature review. Translational Lung Cancer Research, 2020, 9, 1629-1638.	2.8	7

#	ARTICLE	IF	CITATIONS
19	World Lung Day: what, why, and where to?. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2020, 319, L527-L533.	2.9	6
20	A Randomized Controlled Trial of a Non-pharmacological Intervention for Cancer-Related Dyspnea. Frontiers in Oncology, 2020, 10, 591610.	2.8	7
21	Management of Lung Nodules and Lung Cancer Screening During the COVID-19 Pandemic. Journal of the American College of Radiology, 2020, 17, 845-854.	1.8	17
22	Protocol and Rationale for the International Lung Screening Trial. Annals of the American Thoracic Society, 2020, 17, 503-512.	3.2	56
23	Is tissue still the issue in detecting molecular alterations in lung cancer?. Respirology, 2020, 25, 933-943.	2.3	31
24	Management of Lung Nodules and Lung Cancer Screening During the COVID-19 Pandemic. Chest, 2020, 158, 406-415.	0.8	95
25	Diagnosis and treatment of early lung cancer. Australian Journal of General Practice, 2020, 49, 508-512.	0.8	4
26	Prevention and Early Detection for NSCLC: Advances in Thoracic Oncology 2018. Journal of Thoracic Oncology, 2019, 14, 1513-1527.	1.1	83
27	Cost of screening for lung cancer in Australia. Internal Medicine Journal, 2019, 49, 1392-1399.	0.8	8
28	The cytotoxic, inflammatory and oxidative potential of coconut oil-substituted diesel emissions on bronchial epithelial cells at an air-liquid interface. Environmental Science and Pollution Research, 2019, 26, 27783-27791.	5.3	14
29	Summary of the Japanese Respiratory Society statement for the treatment of lung cancer with comorbid interstitial pneumonia. Respiratory Investigation, 2019, 57, 512-533.	1.8	36
30	A Targeted Approach to the Complications of Targeted Therapy. Journal of Thoracic Oncology, 2019, 14, 577-579.	1.1	3
31	Whole-genome sequencing of human malignant mesothelioma tumours and cell lines. Carcinogenesis, 2019, 40, 724-734.	2.8	24
32	Evaluation of an innovative mobile health programme for the self-management of chronic obstructive pulmonary disease (MH-COPD): protocol of a randomised controlled trial. BMJ Open, 2019, 9, e025381.	1.9	12
33	Air pollution in the Asia-Pacific Region. Respirology, 2019, 24, 484-491.	2.3	23
34	Primary human bronchial epithelial cell responses to diesel and biodiesel emissions at an air-liquid interface. Toxicology in Vitro, 2019, 57, 67-75.	2.4	12
35	EGFR mutations in lung cancer: not all equal in the eyes of the immune system?. Annals of Translational Medicine, 2019, 7, S326-S326.	1.7	0
36	Cognitive behavioural therapy (CBT) for patients with chronic lung disease and psychological comorbidities undergoing pulmonary rehabilitation. Journal of Thoracic Disease, 2019, 11, S2238-S2253.	1.4	13

#	ARTICLE	IF	CITATIONS
37	Potential clinical utility of multiple target quantitative polymerase chain reaction (qPCR) array to detect microbial pathogens in patients with chronic obstructive pulmonary disease (COPD). Journal of Thoracic Disease, 2019, 11, S2254-S2265.	1.4	4
38	Diagnostic approach to chronic dyspnoea in adults. Journal of Thoracic Disease, 2019, 11, S2117-S2128.	1.4	16
39	Chronic obstructive pulmonary disease (COPD) and lung cancer: common pathways for pathogenesis. Journal of Thoracic Disease, 2019, 11, S2155-S2172.	1.4	76
40	The effect of diesel emission exposure on primary human bronchial epithelial cells from a COPD cohort: N-acetylcysteine as a potential protective intervention. Environmental Research, 2019, 170, 194-202.	7.5	14
41	Somatic mutations and immune checkpoint biomarkers. Respirology, 2019, 24, 215-226.	2.3	9
42	Interstitial lung abnormalities in the Queensland Lung Cancer Screening Study: prevalence and progression over 2 years of surveillance. Internal Medicine Journal, 2019, 49, 843-849.	0.8	12
43	Air Pollution in the Asia-Pacific Region. A Joint Asian Pacific Society of Respiriology/American Thoracic Society Perspective. American Journal of Respiratory and Critical Care Medicine, 2019, 199, 693-700.	5.6	11
44	Cancer screening in Australia: future directions in melanoma, Lynch syndrome, and liver, lung and prostate cancers. Public Health Research and Practice, 2019, 29, .	1.5	5
45	Evaluating the prognostic significance of significant weight loss in patients with stage III non-small cell lung cancer (NSCLC) undergoing definitive chemoradiation (CRT) after FDG-PET staging.. Journal of Clinical Oncology, 2019, 37, e20045-e20045.	1.6	0
46	Clinical management practices of life-threatening asthma: an audit of practices in intensive care. Critical Care and Resuscitation: Journal of the Australasian Academy of Critical Care Medicine, 2019, 21, 53-62.	0.1	2
47	The IASLC Lung Cancer Staging Project: A Renewed Call to Participation. Journal of Thoracic Oncology, 2018, 13, 801-809.	1.1	49
48	Primary Thoracic Cancers Incidentally Detected on CT Attenuation Correction Images During Myocardial Perfusion Scintigraphy. Clinical Lung Cancer, 2018, 19, e575-e579.	2.6	14
49	Consensus minimum data set for lung cancer multidisciplinary teams: Results of a Delphi process. Respirology, 2018, 23, 927-934.	2.3	22
50	Gefitinib for advanced non-small cell lung cancer. The Cochrane Library, 2018, 2018, CD006847.	2.8	44
51	Estimating the Cost-Effectiveness of Lung Cancer Screening with Low-Dose Computed Tomography for High-Risk Smokers in Australia. Journal of Thoracic Oncology, 2018, 13, 1094-1105.	1.1	29
52	RE: Proportion of Never-Smoker Non-Small Cell Lung Cancer Patients at Three Diverse Institutions. Journal of the National Cancer Institute, 2018, 110, 432-432.	6.3	7
53	Clinical Presentation and Prognostic Factors in Lung Cancer. , 2018, , 186-198.e6.		0
54	High-risk respiratory patients' experiences of bronchoscopy with conscious sedation and analgesia: A qualitative study. Journal of Clinical Nursing, 2018, 27, 2740-2751.	3.0	5

#	ARTICLE	IF	CITATIONS
55	Diagnosis of the cause of chronic dyspnoea in primary and tertiary care: characterizing diagnostic confidence. <i>Journal of Thoracic Disease</i> , 2018, 10, 3745-3756.	1.4	7
56	Editorial on PanCan study. <i>Translational Lung Cancer Research</i> , 2018, 7, S57-S59.	2.8	0
57	Subtype variation and actionability of telomere length abnormality in lung cancer. <i>Translational Lung Cancer Research</i> , 2018, 7, S251-S253.	2.8	3
58	How to optimize the treatment strategy for patients with EGFR-mutant stage IA lung adenocarcinoma: an international multidisciplinary team. <i>Journal of Thoracic Disease</i> , 2018, 10, 3883-3890.	1.4	2
59	Lung Cancer Stigma across the Social Network: Patient and Caregiver Perspectives. <i>Journal of Thoracic Oncology</i> , 2018, 13, 1443-1453.	1.1	22
60	Non-small cell lung cancer brain metastasis screening in the era of positron emission tomography-CT staging: Current practice and outcomes. <i>Journal of Medical Imaging and Radiation Oncology</i> , 2018, 62, 383-388.	1.8	23
61	Does presentation at multidisciplinary team meetings improve lung cancer survival? Findings from a consecutive cohort study. <i>Lung Cancer</i> , 2018, 124, 199-204.	2.0	51
62	Incidental Pulmonary Malignancies on CTAC in MPS. <i>Clinical Lung Cancer</i> , 2018, 19, e801-e802.	2.6	0
63	Identifying high risk individuals for targeted lung cancer screening: Independent validation of the PLCO <sub>2012</sub> risk prediction tool. <i>International Journal of Cancer</i> , 2017, 141, 242-253.	5.1	73
64	P1.05-015 Genomic Characterization of Non-Small Cell Lung Cancer in an Australian Population. <i>Journal of Thoracic Oncology</i> , 2017, 12, S622-S623.	1.1	1
65	The effect of different radiological models on diagnostic accuracy and lung cancer screening performance. <i>Thorax</i> , 2017, 72, 1147-1150.	5.6	14
66	Radiation therapy for preventing instrumentation track metastases in malignant pleural mesothelioma. <i>The Cochrane Library</i> , 2017, , .	2.8	1
67	Low tumour cell content in a lung tumour bank: implications for molecular characterisation. <i>Pathology</i> , 2017, 49, 611-617.	0.6	3
68	A pragmatic, phase III, multisite, double-blind, placebo-controlled, parallel-arm, dose increment randomised trial of regular, low-dose extended-release morphine for chronic breathlessness: Breathlessness, Exertion And Morphine Sulfate (BEAMS) study protocol. <i>BMJ Open</i> , 2017, 7, e018100.	1.9	27
69	Is Digital Tomosynthesis on Par With Computed Tomography for the Detection and Measurement of Pulmonary Nodules?. <i>Journal of Thoracic Imaging</i> , 2017, 32, W67-W68.	1.5	1
70	Immune checkpoint inhibitors (anti PD-1 or anti PD-L1) versus chemotherapy for second- or third-line treatment of metastatic non-small cell lung cancer. <i>The Cochrane Library</i> , 2017, , .	2.8	0
71	Genomics of lung cancer. <i>Journal of Thoracic Disease</i> , 2017, 9, E155-E157.	1.4	2
72	Molecular Basis of Lung Carcinogenesis. , 2017, , 447-496.		4

#	ARTICLE	IF	CITATIONS
73	Inhaled corticosteroids for stable chronic obstructive pulmonary disease. The Cochrane Library, 2016, 2016, CD002991.	2.8	281
74	Lung cancer screening in Australia: progress or procrastination?. Medical Journal of Australia, 2016, 204, 4-5.	1.7	14
75	General medicine Indigenous outreach registrar training in rural Queensland. Medical Journal of Australia, 2016, 205, 237-237.	1.7	0
76	Endobronchial Silicosis and Tuberculosis Presenting as the Right Middle Lobe Syndrome. Journal of Bronchology and Interventional Pulmonology, 2016, 23, e35-e37.	1.4	4
77	Update in lung cancer: epilogue to a modern review series. Respiriology, 2016, 21, 789-790.	2.3	5
78	Brief Tailored Smoking Cessation Counseling in a Lung Cancer Screening Population is Feasible: A Pilot Randomized Controlled Trial: Table 1.. Nicotine and Tobacco Research, 2016, 18, 1665-1669.	2.6	35
79	Screen-detected subsolid pulmonary nodules: long-term follow-up and application of the PanCan lung cancer risk prediction model. British Journal of Radiology, 2016, 89, 20160016.	2.2	18
80	Ethnicity affects EGFR and KRAS gene alterations of lung adenocarcinoma. Oncology Letters, 2015, 10, 1775-1782.	1.8	27
81	Platinum versus non-platinum chemotherapy regimens for small cell lung cancer. The Cochrane Library, 2015, 2015, CD006849.	2.8	39
82	The effectiveness of lung cancer <scp>MDT</scp> and the role of respiratory physicians. Respiriology, 2015, 20, 884-888.	2.3	24
83	Update in lung cancer: Prologue to a modern review series. Respiriology, 2015, 20, 183-184.	2.3	12
84	Lung cancer screening feasibility in Australia. European Respiratory Journal, 2015, 45, 1734-1737.	6.7	24
85	Psychological distress and quality of life in lung cancer: the role of healthâ€related stigma, illness appraisals and social constraints. Psycho-Oncology, 2015, 24, 1569-1577.	2.3	92
86	DNA methylation transcriptionally regulates the putative tumor cell growth suppressor <i>ZNF677</i> in non-small cell lung cancers. Oncotarget, 2015, 6, 394-408.	1.8	27
87	Indigenous Respiratory Outreach Care: the first 18 months of a specialist respiratory outreach service to rural and remote Indigenous communities in Queensland, Australia. Australian Health Review, 2014, 38, 447.	1.1	17
88	Fineâ€needle aspiration diagnosis of sclerosing hemangioma (pneumocytoma): Report of a case and review of the literature. Diagnostic Cytopathology, 2014, 42, 242-246.	1.0	17
89	MicroRNA-34c is associated with emphysema severity and modulates SERPINE1 expression. BMC Genomics, 2014, 15, 88.	2.8	76
90	Electromagnetic navigation bronchoscopy for the diagnosis of <scp> <i>A</i> </scp> <i>aspergillus</i> infection. Respiriology Case Reports, 2014, 2, 30-32.	0.6	2

#	ARTICLE	IF	CITATIONS
91	A retrospective study of volume doubling time in surgically resected non-small cell lung cancer. <i>Respirology</i> , 2014, 19, 755-762.	2.3	33
92	A Large-Scale RNAi-Based Mouse Tumorigenesis Screen Identifies New Lung Cancer Tumor Suppressors That Repress FGFR Signaling. <i>Cancer Discovery</i> , 2014, 4, 1168-1181.	9.4	15
93	Coronary Artery Calcification on Computed Tomography Correlates With Mortality in Chronic Obstructive Pulmonary Disease. <i>Journal of Computer Assisted Tomography</i> , 2014, 38, 753-759.	0.9	19
94	The potential of genome-wide analyses to improve non-small-cell lung cancer care. <i>Lung Cancer Management</i> , 2014, 3, 383-396.	1.5	0
95	Implementing clinical guidelines for chronic obstructive pulmonary disease: barriers and solutions. <i>Journal of Thoracic Disease</i> , 2014, 6, 1586-96.	1.4	42
96	Biomarkers of progression of chronic obstructive pulmonary disease (COPD). <i>Journal of Thoracic Disease</i> , 2014, 6, 1532-47.	1.4	111
97	Genome-wide CpG island methylation analyses in non-small cell lung cancer patients. <i>Carcinogenesis</i> , 2013, 34, 513-521.	2.8	67
98	Mediastinal Abscess After Endobronchial Ultrasound-Guided Transbronchial Needle Aspiration. <i>Journal of Bronchology and Interventional Pulmonology</i> , 2013, 20, 338-341.	1.4	21
99	Peripheral compartment innate immune response to <i>Haemophilus influenzae</i> and <i>Streptococcus pneumoniae</i> in chronic obstructive pulmonary disease patients. <i>Innate Immunity</i> , 2013, 19, 428-437.	2.4	4
100	Personalizing and targeting therapy for COPD – the role of molecular and clinical biomarkers. <i>Expert Review of Respiratory Medicine</i> , 2013, 7, 593-605.	2.5	12
101	Glycopyrronium bromide for chronic obstructive pulmonary disease. <i>The Cochrane Library</i> , 2013, , .	2.8	1
102	Inhaled corticosteroids for subacute and chronic cough in adults. <i>The Cochrane Library</i> , 2013, 2013, CD009305.	2.8	20
103	Digital tomosynthesis for the detection and management of pulmonary nodules. <i>Lung Cancer Management</i> , 2013, 2, 5-7.	1.5	0
104	Phenotypes and Karyotypes of Human Malignant Mesothelioma Cell Lines. <i>PLoS ONE</i> , 2013, 8, e58132.	2.5	23
105	Genetic susceptibility to lung cancer and co-morbidities. <i>Journal of Thoracic Disease</i> , 2013, 5 Suppl 5, S454-62.	1.4	49
106	Screening for lung cancer with low-dose computed tomography: a review of current status. <i>Journal of Thoracic Disease</i> , 2013, 5 Suppl 5, S524-39.	1.4	41
107	An emerging place for lung cancer genomics in 2013. <i>Journal of Thoracic Disease</i> , 2013, 5 Suppl 5, S491-7.	1.4	22
108	Guidelines for the diagnosis and treatment of malignant pleural mesothelioma. <i>Journal of Thoracic Disease</i> , 2013, 5, E254-307.	1.4	170

#	ARTICLE	IF	CITATIONS
109	Should we screen for lung cancer in Australia?. Medical Journal of Australia, 2013, 199, 585-586.	1.7	0
110	Lung cancer. Journal of Thoracic Disease, 2013, 5 Suppl 5, S452-3.	1.4	0
111	Personalized medicine for lung cancer. Lung Cancer Management, 2012, 1, 83-86.	1.5	2
112	Pleural fluid cell-free DNA integrity index to identify cytologically negative malignant pleural effusions including mesotheliomas. BMC Cancer, 2012, 12, 428.	2.6	46
113	Genetic influences on right ventricular systolic pressure (RVSP) in chronic obstructive pulmonary disease (COPD). BMC Pulmonary Medicine, 2012, 12, 25.	2.0	7
114	Hospital activity data inaccurate for determining spread of disease at diagnosis for non-small cell lung cancer. Australian and New Zealand Journal of Public Health, 2012, 36, 212-217.	1.8	1
115	The science behind the 7th edition Tumour, Node, Metastasis staging system for lung cancer. Respiriology, 2012, 17, 247-260.	2.3	23
116	Respiratory health effects of diesel particulate matter. Respiriology, 2012, 17, 201-212.	2.3	247
117	Genomics and the respiratory effects of air pollution exposure. Respiriology, 2012, 17, 590-600.	2.3	70
118	Array-Comparative Genomic Hybridization Reveals Loss of SOCS6 Is Associated with Poor Prognosis in Primary Lung Squamous Cell Carcinoma. PLoS ONE, 2012, 7, e30398.	2.5	28
119	MS4A1 Dysregulation in Asbestos-Related Lung Squamous Cell Carcinoma Is Due to CD20 Stromal Lymphocyte Expression. PLoS ONE, 2012, 7, e34943.	2.5	27
120	Whole genome sequencing for lung cancer. Journal of Thoracic Disease, 2012, 4, 155-63.	1.4	28
121	Electromagnetic navigation bronchoscopy: A descriptive analysis. Journal of Thoracic Disease, 2012, 4, 173-85.	1.4	75
122	Diagnostic molecular biomarkers for malignant pleural effusions. Future Oncology, 2011, 7, 737-752.	2.4	61
123	Lung cancer clinicians' preferences for adjuvant chemotherapy in non-small-cell lung cancer: What makes it worthwhile?. Lung Cancer, 2011, 72, 213-218.	2.0	17
124	Genes and Gene Ontologies Common to Airflow Obstruction and Emphysema in the Lungs of Patients with COPD. PLoS ONE, 2011, 6, e17442.	2.5	26
125	Common pathogenic mechanisms and pathways in the development of COPD and lung cancer. Expert Opinion on Therapeutic Targets, 2011, 15, 439-456.	3.4	77
126	ADAM28: A potential oncogene involved in asbestos-related lung adenocarcinomas. Genes Chromosomes and Cancer, 2010, 49, 688-698.	2.8	24

#	ARTICLE	IF	CITATIONS
127	MicroRNA-218 Is Deleted and Downregulated in Lung Squamous Cell Carcinoma. PLoS ONE, 2010, 5, e12560.	2.5	100
128	Leeuwenhoek's disease: diaphragmatic flutter in a cardiac patient. Cardiology in the Young, 2010, 20, 334-336.	0.8	5
129	EGFR Mutation Testing in Non-Small Cell Lung Cancer. Current Respiratory Medicine Reviews, 2010, 6, 310-321.	0.2	2
130	Meta- and Pooled Analysis of GSTP1 Polymorphism and Lung Cancer: A HuGE-GSEC Review. American Journal of Epidemiology, 2009, 169, 802-814.	3.4	73
131	Epigenomic targets for the treatment of respiratory disease. Expert Opinion on Therapeutic Targets, 2009, 13, 625-640.	3.4	30
132	Expression profiling identifies genes involved in emphysema severity. Respiratory Research, 2009, 10, 81.	3.6	35
133	Optimal use of advanced technology. Expert Review of Respiratory Medicine, 2009, 3, 9-11.	2.5	0
134	Platinum versus non-platinum chemotherapy regimens for small cell lung cancer. , 2008, , CD006849.		33
135	<i>PIK3CA</i> Mutations and Copy Number Gains in Human Lung Cancers. Cancer Research, 2008, 68, 6913-6921.	0.9	399
136	Lung Asbestos Content in Lungs Resected for Primary Lung Cancer. Journal of Thoracic Oncology, 2008, 3, 569-576.	1.1	6
137	The Impact of Sex and Smoking Status on the Mutational Spectrum of Epidermal Growth Factor Receptor Gene in Non-small Cell Lung Cancer. Clinical Cancer Research, 2007, 13, 5763-5768.	7.0	81
138	Inhaled corticosteroids for stable chronic obstructive pulmonary disease. , 2007, , CD002991.		103
139	Gene Expression Signature Predicts Recurrence in Lung Adenocarcinoma. Clinical Cancer Research, 2007, 13, 2946-2954.	7.0	107
140	Myeloperoxidase G-463A polymorphism and lung cancer: A HuGE Genetic Susceptibility to Environmental Carcinogens pooled analysis. Genetics in Medicine, 2007, 9, 67-73.	2.4	47
141	Arg389Gly- $\beta$ 1-adrenergic receptors determine improvement in left ventricular systolic function in nonischemic cardiomyopathy patients with heart failure after chronic treatment with carvedilol. Pharmacogenetics and Genomics, 2007, 17, 941-949.	1.5	78
142	Gene-environmental interaction in asthma. Current Opinion in Allergy and Clinical Immunology, 2007, 7, 75-82.	2.3	46
143	$\beta$ 2-ADRENOCEPTOR POLYMORPHISMS AND OBSTRUCTIVE AIRWAY DISEASES: IMPORTANT ISSUES OF STUDY DESIGN. Clinical and Experimental Pharmacology and Physiology, 2007, 34, 1029-1036.	1.9	9
144	The role of Toll-like receptors and related receptors of the innate immune system in asthma. Current Opinion in Allergy and Clinical Immunology, 2006, 6, 23-28.	2.3	75

#	ARTICLE	IF	CITATIONS
145	Epigenetics of lung cancer. <i>Respirology</i> , 2006, 11, 355-365.	2.3	52
146	Expression and methylation pattern of TSLC1 cascade genes in lung carcinomas. <i>Oncogene</i> , 2006, 25, 959-968.	5.9	72
147	A Genome-Wide Screen for Promoter Methylation in Lung Cancer Identifies Novel Methylation Markers for Multiple Malignancies. <i>PLoS Medicine</i> , 2006, 3, e486.	8.4	228
148	Expression of the candidate tumor suppressor gene hSRBC is frequently lost in primary lung cancers with and without DNA methylation. <i>Oncogene</i> , 2005, 24, 6249-6255.	5.9	49
149	Clinical and Biological Features Associated With Epidermal Growth Factor Receptor Gene Mutations in Lung Cancers. <i>Journal of the National Cancer Institute</i> , 2005, 97, 339-346.	6.3	2,194
150	An Expression-Based Site of Origin Diagnostic Method Designed for Clinical Application to Cancer of Unknown Origin. <i>Cancer Research</i> , 2005, 65, 4031-4040.	0.9	206
151	Somatic Mutations of the <i>HER2</i> Kinase Domain in Lung Adenocarcinomas. <i>Cancer Research</i> , 2005, 65, 1642-1646.	0.9	641
152	Effectiveness of Hospital-Based Smoking Cessation. <i>Chest</i> , 2005, 128, 216-223.	0.8	22
153	p53 apoptotic pathway molecules are frequently and simultaneously altered in nonsmall cell lung carcinoma. <i>Cancer</i> , 2004, 100, 1673-1682.	4.1	72
154	Characterization of two polymorphisms in the leukotriene C4 synthase gene in an Australian population of subjects with mild, moderate, and severe asthma. <i>Journal of Allergy and Clinical Immunology</i> , 2004, 113, 889-895.	2.9	66
155	(-)-CGP 12177 increases contractile force and hastens relaxation of human myocardial preparations through a propranolol-resistant state of the $\beta_1$ -adrenoceptor. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 2003, 367, 10-21.	3.0	49
156	Smoke exposure, histologic type and geography-related differences in the methylation profiles of non-small cell lung cancer. <i>International Journal of Cancer</i> , 2003, 103, 153-160.	5.1	273
157	'Iron lung': Distinctive bronchoscopic features of acute iron tablet aspiration. <i>Respirology</i> , 2003, 8, 541-543.	2.3	25
158	Epigenetic inactivation of the candidate 3p21.3 suppressor gene BLU in human cancers. <i>Oncogene</i> , 2003, 22, 1580-1588.	5.9	98
159	Molecular Genetics of Lung Cancer. <i>Annual Review of Medicine</i> , 2003, 54, 73-87.	12.2	289
160	Conservation of the cardiostimulant effects of ( $\alpha$ )-norepinephrine across Ser49Gly and Gly389Arg $\beta_1$ -adrenergic receptor polymorphisms in human right atrium in vitro. <i>Journal of the American College of Cardiology</i> , 2002, 40, 1275-1282.	2.8	51
161	Molecular biology of lung cancer: Clinical implications. <i>Clinics in Chest Medicine</i> , 2002, 23, 83-101.	2.1	90
162	The Molecular Basis of Lung Carcinogenesis. , 2002, , 379-405.		4

#	ARTICLE	IF	CITATIONS
163	Role of TSG101 in Uterine Cervix Cancer. Gynecologic Oncology, 1999, 75, 401-405.	1.4	6
164	Molecular pathogenesis of lung cancer. Journal of Thoracic and Cardiovascular Surgery, 1999, 118, 1136-1152.	0.8	119
165	Frequent Loss of KAI1 Expression in Squamous and Lymphoid Neoplasms. American Journal of Pathology, 1999, 154, 1665-1671.	3.8	36
166	TSG101 is not mutated in lung cancer but a shortened transcript is frequently expressed in small cell lung cancer. Oncogene, 1998, 17, 1141-1148.	5.9	30
167	Mutation analysis of the PTEN/MMAC1 gene in lung cancer. Oncogene, 1998, 17, 1557-1565.	5.9	181
168	Progress in understanding the molecular pathogenesis of human lung cancer. Biochimica Et Biophysica Acta: Reviews on Cancer, 1998, 1378, F21-F59.	7.4	147
169	Allelotyping demonstrates common and distinct patterns of chromosomal loss in human lung cancer types. , 1998, 21, 308-319.		158
170	Abnormalities of Fragile Histidine Triad Genomic and Complementary DNAs in Cervical Cancer: Association With Human Papillomavirus Type. Journal of the National Cancer Institute, 1998, 90, 433-439.	6.3	49
171	Precise localization of theFHIT gene to the common fragile site at 3p14.2 (FRA3B) and characterization of homozygous deletions within FRA3B that affectFHIT transcription in tumor cell lines. , 1997, 20, 16-23.		24
172	Lung pathology: the molecular genetics of non-small cell lung cancer. Pathology, 1995, 27, 295-301.	0.6	7
173	Human papillomavirus not found in squamous and large cell lung carcinomas by polymerase chain reaction. Cancer, 1995, 75, 2400-2401.	4.1	10
174	Correlation of loss of heterozygosity at 11 p with tumour progression and survival in non-small cell lung cancer. Genes Chromosomes and Cancer, 1994, 10, 183-189.	2.8	48
175	Gefitinib for advanced non-small cell lung cancer. The Cochrane Library, 0, , .	2.8	3
176	The current and future roles of genomics. , 0, , 79-94.		0